Preclinical Dose-Formulation Stability - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Preclinical Dose-Formulation Stability
A number of factors need to be considered when evaluating preclinical dose-formulation stability. The authors discuss formulation, storage and dosing conditions.

Pharmaceutical Technology Europe
Volume 24, Issue 6

Stability considerations

Stability assessments of preclinical dosing formulations need to consider conditions that are representative of the formulation process used for preparing the dose preparation. Specifically, preparations manufactured in an analytical laboratory to evaluate method performance may not be representative of the process used in the formulation laboratory and, therefore, may not be appropriate for use in assessing stability. Differences in scale, equipment, and mixing methods may need to be considered. For example, heat generated from the use of high speed mixers in a dosing batch may not have been apparent during the preparation of a small-scale batch. As such, direct heating of the dosing batch may be required. Extended or overnight mixing times also may be required for a dosing batch where they may not be required for a small-scale validation batch. These variables need to be considered when establishing an appropriate stability protocol to ensure stability batches are representative of dosing batches.

Stability data need to cover the conditions encountered during dosing in the in vivo studies. Related to dosing, physical stability becomes just as crucial as chemical stability. Questions related to maintaining a viable suspension or homogeneous mixture during the dosing period may need to be considered and addressed. In situations where dosing formulations have known stability issues, either chemical or physical adjustments may be needed for dosing. Conditions such as preparing the dose formulation under yellow light, temperature control, continuous stirring and timed dosing are all strategies that may be used to ensure that the integrity of the dosing formulation material remains intact. For example, a dose-formulation was found to be chemically stable for 48 hours at ambient temperature and observed recoveries were near 100% of the time-zero value. An optimal dosing viscosity, however, could not be maintained at ambient temperature and the material required heating before and during dosing. As a consequence, heating was incorporated into the original stability assessment.

Storage considerations

Consistent with stability assessment for drug products, storage of preclinical dose formulations needs to be considered when evaluating stability. This evaluation may range from a simple assessment of material at ambient or refrigerated conditions or for material being used over multiple dosing days and include evaluation of freeze/thaw cycles. Extensive stability programmes, comparable to those designed for drug substances and drug products, are not required as storage and use are tightly controlled.

Stability studies on dose formulations are required to support preclinical regulated studies. While stability protocols for preclinical dose formulations are not as comprehensive as their subsequent drug-substance and drug-product programmes, the information they provide to support an in vivo study is critical. Development of stability studies requires consideration of formulation, dosing, and storage to ensure the stability data collected are directly relevant to the in vivo study conditions.

Amy Smith is director of analytical laboratory operations and Melissa Whitsel is analytical manager, both with MPI Research; headquarters located at 54943 North Main Street, Mattawan, MI 49071


1. FDA, 21 CFR Part 58 Good Laboratory Practice Regulations Final Rule (Rockville, MD, 1987).

2. M.B. Whitmire, AAPS Jrnl., 12 (4) (2010).

3. ICH, Q1A(R2) Stability Testing of New Drug Substances and Products (2003)

4. ICH, Q2(R1) Validation of Analytical Procedures: Text and Methodology.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology Europe,
Click here